Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Ultra-low dose estriol vaginal gel effective against vulvovaginal atrophy

17 Mar 2020

Treatment with the ultra-low dose 0.005% estriol vaginal gel yields improvements in symptoms and signs of vulvovaginal atrophy, with minimal oscillations in hormonal levels, according to the results of a phase II trial.

A total of 61 women (mean age, 59 years) with hormone receptor-positive early breast cancer treated with nonsteroidal aromatase inhibitors (NSAIs) were randomly assigned to receive either estriol vaginal gel (n=50) or placebo (n=11) for 12 weeks for their treatment-related vulvovaginal symptoms and signs.

Researchers assessed vaginal maturation, vaginal pH, and vulvovaginal atrophy symptoms and signs at baseline and at weeks 3 and 12. They also evaluated sexual functioning using the Female Sexual Functioning Index (FSFI) questionnaire, in addition to circulating oestrogens, follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Active treatment exerted favourable effects on maturation value and pH, vaginal dryness, and global scores of symptoms and signs. Parallel improvements were seen in the total FSFI score and all the FSFI domains, with the exception of pain.

There were small oscillations in FSH and LH, which remained within the postmenopausal range. Estriol levels increased at the outset but returned to normal by week 12, whereas oestradiol and estrone levels remained mostly undetectable throughout the study.

The present data highlight the usefulness of ultra-low dose 0.005% estriol vaginal gel in the treatment of vulvovaginal atrophy in women with breast cancer receiving NSAIs with an indication for treatment with vaginal oestrogens, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.